CYCN - Cyclerion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.61
-0.10 (-0.68%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.71
Open14.52
Bid0.00 x 1000
Ask0.00 x 900
Day's Range14.27 - 14.98
52 Week Range12.50 - 22.85
Volume96,887
Avg. Volume170,511
Market Cap400.339M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.65
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today provided a general corporate and pipeline overview, as well as financial results for the first quarter of 2019. “Cyclerion launched with the mission of developing life changing medicines for patients suffering from serious and orphan diseases through the modulation of soluble guanylate cyclase,” said Peter Hecht, Ph.D., chief executive officer of Cyclerion. “Our team is advancing a pipeline of differentiated and wholly owned sGC stimulator therapeutic candidates with compelling preclinical and clinical data.

  • GlobeNewswire25 days ago

    Cyclerion to Host Corporate Overview Call on May 13, 2019

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a conference call and live audio webcast on Monday, May 13, 2019 at 8:30 a.m. Eastern Time. For its first webcast conference call as a public company, Cyclerion intends to provide a general corporate overview and discuss its clinical and preclinical development pipeline.

  • Cyclerion taps ex-Shire exec as chief innovation officer
    American City Business Journalslast month

    Cyclerion taps ex-Shire exec as chief innovation officer

    Cyclerion has hired the former chief medical officer at Shire plc for a new, overarching role focused on bridging R&D;, external partnerships and other business facets.

  • GlobeNewswire2 months ago

    Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases

    Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its launch as an independent, publicly traded clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. “We are excited to unleash the terrific Cyclerion team and further our laser-focused mission to advance tailored sGC stimulators to patients with serious and orphan diseases,” said Peter Hecht, chief executive officer of Cyclerion.